Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiol TherapeuticsSTU:CT9 -8.71%27 3-Year EBITDA Growth Rate is 15.80% as of Jun. 2026, which is 98% above its 10-year median of 8.00. GuruFocus rates STU:CT9 with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 808 Drug Manufacturers companies, Cardiol Therapeutics ranks better than 61.39% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 15.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 12.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cardiol Therapeutics was 15.80% per year. The lowest was -116.00% per year. And the median was 8.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cardiol Therapeutics 3-Year EBITDA Growth Rate Related Terms
STU:CT9 vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiol Therapeutics 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cardiol Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 15.80% mean?
Cardiol Therapeutics (STU:CT9) has a 3-Year EBITDA Growth Rate of 15.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cardiol Therapeutics and its competitors. This is 98% above median its historical median of 8.00. According to the industry distribution chart, Cardiol Therapeutics ranks #312 out of 808 companies in the Drug Manufacturers industry, placing it in the top 38.6%.
Is Cardiol Therapeutics' 3-Year EBITDA Growth Rate too high?
Cardiol Therapeutics' current 3-Year EBITDA Growth Rate of 15.80% is 98% above median its 10-year median of 8.00. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Cardiol Therapeutics' value of 15.80% is 77.5% above this industry median. Based on the distribution chart, Cardiol Therapeutics ranks #312 out of 808 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cardiol Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cardiol Therapeutics ranks #312 out of 808 companies for 3-Year EBITDA Growth Rate. This puts Cardiol Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Cardiol Therapeutics' value of 15.80% is 77.5% above this benchmark. While the company's 10-year median is 8.00 vs. the industry median of 8.90, Cardiol Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiol Therapeutics's current 3-Year EBITDA Growth Rate of 15.80% is 77.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cardiol Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiol Therapeutics's current 3-Year EBITDA Growth Rate is 15.80%, which is 98% above median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (STU:CT9) has a current 3-Year EBITDA Growth Rate of 15.80%. The current 3-Year EBITDA Growth Rate is 15.80%, which is 98% above median its 10-year median of 8.00 and 77.5% above the Drug Manufacturers industry median of 8.90. Cardiol Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cardiol Therapeutics (STU:CT9), the current 3-Year EBITDA Growth Rate is 15.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
27GF Score
Get the complete analysis for STU:CT9
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CT9 has been successfully added to your 
